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Obese leptin-deficient ob/ob mice exhibit a low-grade chronic inflammation together with a low muscle mass. Our aim was to
analyze the changes in muscle expression levels of genes related to oxidative stress and inflammatory responses in leptin deficiency
and to identify the eﬀect of in vivo leptin administration. Ob/ob mice were divided in three groups as follows: control ob/ob, leptin-
treated ob/ob (1 mg/kg/d) and leptin pair-fed ob/ob mice. Gastrocnemius weight was lower in control ob/ob than in wild type mice
(P < .01) exhibiting an increase after leptin treatment compared to control and pair-fed (P < .01) ob/ob animals. Thiobarbituric
acid reactive substances, markers of oxidative stress, were higher in serum (P < .01) and gastrocnemius (P = .05) of control ob/ob
than in wild type mice and were significantly decreased (P < .01) by leptin treatment. Leptin deficiency altered the expression
of 1,546 genes, while leptin treatment modified the regulation of 1,127 genes with 86 of them being involved in oxidative stress,
immune defense and inflammatory response. Leptin administration decreased the high expression of Crybb1, Hspb3, Hspb7, Mt4,
Cat, Rbm9, Serpinc1 and Serpinb1a observed in control ob/ob mice, indicating that it improves inflammation and muscle loss.
1. Introduction
Obesity is associated with a low-grade proinflammatory state
resulting in an increase of circulating cytokines and inflam-
matory markers [1]. Inflammatory cytokines have been
involved in the impairment of insulin signaling, thus provid-
ing molecular links between inflammation and insulin resis-
tance [2]. Inflammation reportedly produces metabolic alter-
ations in skeletal muscle with both inflammatory response
and insulin resistance being associated with loss of muscle
mass by decreased protein synthesis and increased proteolysis
[3–5]. Recently, our group has shown that leptin reverses
muscle loss of ob/ob mice by inhibiting the activity of the
transcriptional factor forkhead box class O3a (FoxO3a) [6].
Leptin is an adipocyte-derived peptidic hormone [7] that
inhibits food intake and increases thermogenesis by acting
through its hypothalamic receptors [8, 9]. Leptin-deficient
ob/ob mice are obese, hyperphagic, exhibit type 2 diabetes,
decreased body temperature and hypogonadotropic hypog-
onadism [10]. Leptin is a member of the long-chain helical
cytokine family and its receptors, which belong to the class I
cytokine receptors, are present in bone marrow and spleen as
well as on peripheral monocytes and lymphocytes [1]. Leptin
increases in response to acute infection and sepsis and it has
been reported to exert a profound influence on the function
and proliferation of T lymphocytes and natural killer cells
[11], on the phagocytosis of macrophages/monocytes [12],
and to have a direct eﬀect on the secretion of anti- and
proinflammatory cytokines [13]. In this regard, impaired
cellular and humoral immunity have been shown in leptin-
deficient ob/ob mice as well as in leptin receptor-deficient
db/db mice [14, 15]. These studies reflect the molecular
nature of leptin as a cytokine and are consistent with leptin
signaling playing a pivotal role in the pathogenesis of obesity-
associated inflammation and muscle loss.
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In the present paper, gastrocnemius muscle samples
from wild type and ob/ob mice were analyzed for mRNA
presence of over 41,000 transcripts by microarray analysis
to identify genes involved in inflammation and oxidative
stress that are aﬀected by leptin deficiency and leptin
administration in ob/ob mice. It was shown that leptin
increases the gastrocnemius weight and reduces the high
expression levels of genes related to the obesity-associated
low-grade inflammation in skeletal muscle of ob/ob mice.
2. Material and Methods
2.1. Animals and Treatments. Ten-week-old male genetically
obese ob/ob mice (C57BL/6J) (n = 15) and their lean
control littermates wild type (n = 5) supplied by Harlan
(Barcelona, Spain) were housed in a room with controlled
temperature (22±2◦C) and a 12:12 light-dark cycle (lights on
at 08:00 am). Body weight of ob/ob mice was measured before
randomization into control, leptin-treated (1 mg/kg/d) and
pair-fed groups (n = 5 per group). The control and pair-fed
groups received vehicle (PBS), while leptin-treated mice were
intraperitoneally administered with leptin (Bachem, Buben-
dorf, Switzerland) twice daily at 08:00 am and 08:00 pm for
28 days. Control and leptin-treated groups were provided
with water and food ad libitum with a standard rodent chow
(2014S Teklad, Harlan), while daily food intake of the pair-
fed group was matched to the amount consumed by the
leptin-treated group the day before in order to discriminate
the inhibitory eﬀect of leptin on appetite. Animals were
sacrificed on the 28th day of treatment by CO2 inhalation
20 hours after the last PBS or leptin administration (in order
to avoid picking up eﬀects reflecting an acute response) and
after 8 hours of fasting. Serum samples and gastrocnemius
muscles were obtained and stored at−80◦C. All experimental
procedures conformed to the European Guidelines for the
Care and Use of Laboratory Animals (directive 86/609)
and were approved by the Ethical Committee for Animal
Experimentation of the University of Navarra (080/05).
2.2. Blood Analysis. Serum glucose was analyzed using a
sensitive-automatic glucose sensor (Ascensia Elite, Bayer,
Barcelona, Spain). Free fatty acid (FFA) concentrations were
measured by a colorimetric determination using the NEFA
C kit (WAKO Chemicals, Neuss, Germany). Serum glycerol
concentrations were evaluated by enzymatic methods as
previously described [6]. Serum triglycerides (TG) con-
centrations were spectrophotometrically determined using
a commercial kit (Infinity, Thermo Electron, Melbourne,
Australia). Insulin and leptin were determined using spe-
cific mouse ELISA kits (Crystal Chem Inc., Chicago, IL,
USA). Intra- and interassay coeﬃcients of variation for
measurements of insulin and leptin were 3.5% and 6.3%,
respectively, for the former, and 2.8% and 5.8%, for the
latter. Adiponectin concentrations were also assessed using
a mouse ELISA kit (BioVendor Laboratory Medicine, Inc.,
Modrice, Czech Republic). Intra- and interassay coeﬃcients
of variation for adiponectin were 2.6% and 5.3%, respec-
tively. Insulin resistance was calculated using the homeostasis
model assessment score (HOMA; fasting insulin (μU/mL)
× fasting glucose (mmol/L)/22.5) [16]. An indirect measure
of insulin sensitivity was calculated by using the quantita-
tive insulin sensitivity check index (QUICKI; 1/[log(fasting
insulin mU/mL) + log(fasting glucose mg/dL)] [17].
Lipid peroxidation was analyzed by the measurement of
thiobarbituric acid reactive substances (TBARS) in serum
and gastrocnemius as previously described by Conti et
al. [18] with some modifications. Since the best-known
specific TBARS is malondialdehyde (MDA), we used serum
MDA levels, a secondary product of lipid peroxidation,
as an indicator of lipid peroxidation and oxidative stress.
Gastrocnemius samples (20–30 mg) were homogenized in
20 volumes of phosphate buﬀer pH 7.4. Serum, muscle
homogenates (5 μL) or standard (MDA) were mixed with
120 μL of diethyl thiobarbituric acid (DETBA) 10 mM and
vortexed for 5 seconds. The reaction mixture was then
incubated at 95◦C for 60 minutes. After cooling to room
temperature DETBA-MDA adducts were extracted in 360 μL
n-butanol vortexing for 1 minute and centrifuged at 1,600 g
for 10 minutes at room temperature. Then, the chromophore
of the DETBA-MDA adduct was quantified in 200 μL of the
upper butanol phase by fluorescence emission at 535 nm
with an excitation at 590 nm. MDA equivalents (TBARS)
were quantified using a calibration curve prepared using
MDA standard working solutions and expressed as serum
MDA μM and gastrocnemius MDA μM/mg protein. Protein
concentrations were determined using a Bradford protein
assay kit (BioRad, Hercules, CA, USA).
2.3. Microarray Experiments and Analysis. Total RNA was
extracted from 20–30 mg of gastrocnemius muscle samples
by homogenization with an ULTRA-TURRAX T 25 basic
(IKA Werke GmbH, Staufen, Germany) using TRIzol reagent
(Invitrogen, Barcelona, Spain). RNA was purified using the
RNeasy Mini kit (Qiagen, Barcelona, Spain) and treated with
DNase I (RNase-free DNase Set, Qiagen) in order to remove
any trace of genomic DNA.
Gene expression analyses were conducted using the
Agilent Whole Mouse Genome array (G4121B, Agilent
Technologies, Santa Clara, CA, USA) containing ∼41, 000
mouse genes and transcripts. Fluorescence-labeled cDNA
probes were prepared from 1 μg of total RNA from each
sample (5 animals per group) to be subsequently amino-
allyl labeled and amplified using the Amino Allyl Mes-
sageAmp II aRNA Amplification Kit (Ambion, Austin, TX,
USA). Aliquots (1.2 μg) of amplified aRNA were fluo-
rescently labeled using Cy3/Cy5 (Amersham Biosciences,
Buckinghamshire, UK) and then appropriately combined
and hybridized to Agilent microarrays. Hybridizations were
performed following a reference design, where control
samples were pools of RNA from all individual samples.
Two hybridizations with fluor reversal (Dye-swap) were
performed for each sample. After washing, microarray slides
were scanned using a Gene Pix 4100A scanner (Axon
Instruments, Union City, CA, USA) and image quantization
was performed using the software GenePiX Pro 6.0. Gene
expression data for all replicate experiments were analyzed
using the GeneSpring GX software version 7.3.1 (Agilent
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Table 1: Sequences of the primers and Taqman probes used in the Real-Time PCR.
Gene Gene Symbol GenBank Oligonucleotide sequence (5′-3′)
accesio´n number
Peroxisome
proliferator-activated
receptor-γ coactivator-1α
Pgc1a NM 008904 Forward: GTCTGAAAGGGCCAAACAGAGA
Reverse: TCAATTCTGTCCGCGTTGTG
Probe: FAM-AGCAGAAAGCAATTGAAGAGCGCCGT-TAMRA
Forkhead box O1 Foxo1 NM 019739 Forward: GCGGGCTGGAAGAATTCAAT
Reverse: TCCTTCATTCTGCACTCGAATAAACT
Probe: FAM-CGCCACAATCTGTCCCTTCACA-TAMRA
Muscle atrophy F box MAFbx NM 026346 Forward: CCATCCTGGATTCCAGAAGATTC
Reverse: TCAGGGATGTGAGCTGTGACTTT
Probe: FAM-CTACGTAGTAAGGCTGTTGGAGCTGAT-TAMRA
Muscle RING finger 1 MuRF1 NM 001039048 Forward: CGCCATGAAGTGATCATGGA
Reverse: TCCTTGGAAGATGCTTTGCA
Probe: FAM-TGTACGGCCTGCAGAGGAACCTGAAA-TAMRA
Technologies). Clustering was accomplished with the Gene
and Condition Tree algorithms. In addition, Gene Ontology
database (http://babelomics.bioinfo.cipf.es) and the KEGG
website (http://www.genome.ad.jp/kegg/pathway) were used
in conjunction with GeneSpring (http://www.agilent.com/ch
-em/genespring) to identify pathways and functional groups
of genes. All microarray data reported are described in ac-
cordance with MIAME guidelines (http://www.mged.org/
Workgroups/MIAME/miame.html). More information rega-
rding the microarray experiments can be found at the
EMBL-European Bioinformatics Institute (http://www.ebi.ac
.uk/aerep/login. ArrayExpress accession number: E-MEXP-
1831). To validate the microarray data, a number of repre-
sentative diﬀerentially expressed genes were selected to be
individually studied by Real-Time PCR (7300 Real Time
PCR System, Applied Biosystems, Foster City, CA, USA)
(n = 5 per group) as previously described [19]. Primers and
probes were designed using the software Primer Express 2.0
(Applied Biosystems) and purchased from Genosys (Sigma,
Madrid, Spain) (Table 1).
2.4. Statistical Analysis. Data are expressed as mean ±
standard error of the mean (SEM). Diﬀerences between
groups were assessed by Kruskal-Wallis followed by Mann
Whitney’s U test. As previously outlined, Gene Ontology
groupings were used to identify pathways significantly
aﬀected by leptin deficiency as opposed to its administration.
Furthermore, statistical comparisons for microarray data to
identify diﬀerentially expressed genes across diﬀerent groups
were performed using one-way ANOVA and Student’s t-tests
as appropriate. Spearman’s correlations were used to evaluate
the relations among diﬀerent variables. All statistical analyses
were performed by using the SPSS statistical program version
15.0 for Windows (SPSS, Chicago, IL, USA) and statistical
significance was defined as P < .05.
3. Results
3.1. Leptin Treatment Improves the Metabolic Profile of ob/ob
Mice. The morphological and biochemical characteristics
of wild type and ob/ob mice are reported in Table 2. As
expected, leptin treatment corrected the obese and diabetic
phenotype of ob/ob mice. Body weight was significantly
higher (P < .01) in the control ob/ob group as compared
to wild type mice. Leptin-treated mice exhibited a decreased
body weight (P < .01) as compared to control and pair-
fed ob/ob animals. Importantly, leptin treatment normalized
body weight of ob/ob mice as compared to wild type (P =
.690). In addition, the gastrocnemius of control ob/ob mice
exhibited a lower (P < .01) muscle weight than that of
wild type mice and it was increased (P < .01) by leptin
administration in comparison with that of control and pair-
fed ob/ob rodents. As depicted in Table 2, higher fasting
glucose (P < .05) and insulin (P < .01) concentrations
were observed in the control ob/ob mice compared to wild
types. Although no diﬀerences in glucose concentrations
were observed in pair-fed as compared to leptin-treated ob/ob
mice, higher serum insulin concentrations (P < .05) were
detected in the pair-fed animals than in the leptin-treated
ob/ob group. Furthermore, leptin administration normalized
both the glucose and insulin levels in ob/ob mice compared to
wild types. These data suggest that leptin increases the insulin
sensitivity in peripheral tissues, as evidenced by the lower
HOMA and higher QUICKI indices (P < .01) in the leptin-
treated in comparison with the control ob/ob animals. Serum
glycerol was markedly increased (P < .05) in the control
ob/ob mice, while FFA and TG levels remained unchanged
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Table 2: Total body and skeletal muscle weights and biochemical characteristics of wild type and ob/ob mice.
wild type control ob/ob pair-fed ob/ob leptin-treated ob/ob
Body weight (g) 25.6± 0.3 47.8± 4.9b 35.7± 0.7 24.7± 1.2d,f
Gastrocnemius (mg) 142.9± 3.4 90.7± 10.0b 68.5± 1.6 104.9± 2.6b,f
Gastrocnemius (mg/g) 5.59± 0.12 1.91± 0.11b 1.92± 0.07 4.28± 0.15b,d,f
Glucose (mg/dL) 149± 42 430± 59a 160± 24d 178± 29d
FFA (mmol/L) 1.62± 0.49 1.61± 0.30 1.65± 0.12 0.78± 0.13c,f
Glycerol (mmol/L) 42.8± 6.7 81.6± 19.6a 39.6± 4.9c 12.3± 4.7a,d,f
TG (mg/dL) 122± 18 169± 32 151± 10 86± 17e
Insulin (ng/mL) 0.42± 0.09 8.60± 1.51b 2.40± 0.68c 0.47± 0.09d,e
Adiponectin (μg/mL) 30.2± 3.0 28.3± 5.4 39.1± 1.8 40.2± 3.0
Leptin (ng/mL) 1.36± 0.42 UD UD 3.48± 1.02
HOMA 4.3± 1.8 202.4± 33.8b 25.8± 10.4d 5.12± 1.1d
QUICKI 0.333± 0.023 0.205± 0.003b 0.263± 0.015d 0.311± 0.016d
Data are mean±SEM (n = 5 per group). Diﬀerences between groups were analyzed by Kruskal-Wallis followed by Mann Whitney’s U test. aP < .05 and bP <
.01versus wild type. cP < .05 and dP < .01 versus ob/ob. eP < .05 and fP < .01 versus pair-fed ob/ob. FFA: free fatty acids. TG: triglycerides. UD: undetectable.
HOMA: homeostasis model assessment. QUICKI: quantitative insulin sensitivity check index.
0
1
2
3
4
5
T
B
A
R
S
(M
D
A
μ
M
) 6
7
8
∗∗ ∗∗
∗∗
∗
Wild type
Control ob/ob
Pair-fed ob/ob
Leptin-treated ob/ob
(a)
0
10
20
30
40
T
B
A
R
S
(M
D
A
μ
M
/m
g
pr
ot
)
50
∗
∗∗
Wild type
Control ob/ob
Pair-fed ob/ob
Leptin-treated ob/ob
(b)
Figure 1: Leptin reduces TBARS concentrations in ob/ob mice. Thiobarbituric acid reactive substances (TBARS) presented as concentrations
of malondialdehyde (MDA μM) in serum (a) and gastrocnemius muscle (MDA μM/mg prot) (b) of wild type (open), control ob/ob (closed),
pair-fed ob/ob (gray) and leptin-treated ob/ob (striped) mice (n = 5 per group). Data are expressed as mean± SEM. ∗P < .05 and ∗∗P < .01
by Kruskal-Wallis followed by Mann Whitney’s U test.
as compared to wild type mice. Interestingly, leptin not
only decreased circulating concentrations of FFA (P < .05)
and glycerol (P < .01) levels as compared to control ob/ob
mice, but also FFA (P < .01), glycerol (P < .01) and TG
(P < .05) concentrations as compared to pair-fed mice.
Leptin administration to ob/ob mice reduced serum glycerol
concentrations (P = .032) and tended to decrease FFA
(P = .095) as compared to wild types. Furthermore, leptin
treatment increased the low concentrations of adiponectin
of ob/ob mice, but the diﬀerences fell out of statistical
significance (P = .095).
Control ob/ob mice exhibited significantly higher
serum TBARS than wild type littermates (P < .01), which
were significantly reduced after leptin administration as
compared to the control (P < .01) and pair-fed (P < .05)
ob/ob groups (Figure 1(a)). In addition, leptin decreased
(P < .01) the high concentrations of MDA measured in
the gastrocnemius muscle of control ob/ob mice, while this
eﬀect was not observed in the pair-fed group (Figure 1(b)).
Serum and gastrocnemius TBARS levels were positively
associated with body weight, FFA, insulin, and the HOMA
index. Oppositely, TBARS levels were negatively associated
with adiponectin and the QUICKI index both in serum and
muscle. Importantly, a high positive relation were found
between serum and gastrocnemius concentrations of TBARS
(ρ = 0.63, P = .003) (Table 3).
3.2. Leptin Induces Changes in Gene Expression—Eﬀect of
Leptin on Genes Invoved in Oxidative Stress and Inflammation.
Diﬀerential gene expression profiles in gastrocnemius muscle
of wild type and ob/ob groups were compared by microarray
analysis. Only genes whose mRNA levels were changed
Mediators of Inflammation 5
Table 3: Bivariate analysis of the correlations between TBARS
concentrations in serum and the gastrocnemius muscle with
anthropometric and biochemical variables in wild type and ob/ob
mice.
Serum TBARS Gastrocnemius TBARS
ρ P ρ P
Body weight 0.57 .009 0.46 .040
Glucose 0.44 .055 0.38 .103
FFA 0.54 .015 0.59 .007
Glycerol 0.49 <.001 0.44 .053
TG 0.44 .054 0.44 .050
Insulin 0.49 .027 0.52 .020
Adiponectin −0.51 .022 −0.53 .016
QUICKI −0.48 .031 −0.48 .033
HOMA 0.53 .019 0.51 .025
Values are Spearman’s correlation coeﬃcients (ρ) and associated P values.
TBARS: thiobarbituric acid reactive substances. FFA: free fatty acids. TG:
triglycerides. HOMA: homeostasis model assessment. QUICKI: quantita-
tive insulin sensitivity check index.
1.5-fold or higher and identified as significantly changed by
statistical analysis were designated as diﬀerentially expressed
genes. Applying these criteria, microarray data showed that
7,582 genes were diﬀerentially expressed by leptin deficiency
and leptin administration in ob/ob mice. In particular, leptin
deficiency altered the expression of 1,127 genes between wild
type and control ob/ob mice. Of these, 580 were upregulated
and 547 were downregulated in ob/ob mice. Leptin treatment
modified the expression of 1,546 genes in ob/ob mice,
upregulating 512 and repressing 1,034. In addition, leptin
repressed 736 genes that were upregulated in gastrocnemius
muscle of control ob/ob and increased the transcript levels
of 846 downregulated genes. Functional enrichment analysis
using GeneOntology and KEGG databases revealed that the
set of genes with altered expression levels induced by leptin
deficiency and administration represents a broad spectrum
of biological processes. However, for the purpose of the
present paper we focused on the eﬀects of leptin on the set
of genes encoding proteins involved in oxidative stress and
inflammation. Table 4 shows that leptin deficiency and leptin
administration altered the expression of a large number
of genes involved in oxidative stress and inflammation.
The biological processes mainly aﬀected between control
ob/ob mice and wild types included “response to oxidative
stress” (P = .0006), “response to stress” (P = .0031)
and “acute-phase response” (P = .023). Furthermore,
several processes regulating proliferation, diﬀerentiation,
and activity of lymphocytes were also significantly aﬀected by
leptin deficiency. Importantly, comparison of leptin-treated
and control ob/ob groups showed that leptin administration
altered the expression of genes implicated in the “positive
regulation of lymphocyte activation” (P = .0003), “positive
regulation of immune response” (P = .0032) and “response
to stress” (P = .0187), as well as genes involved in the
“chaperone cofactor dependent protein folding” (P = .0023).
Noteworthy, leptin reduced the expression of several
genes related to inflammatory conditions. DNA microarray
analysis showed that 86 genes encoding proteins related to
defense, stress, and inflammatory responses were altered
in the gastrocnemius muscle of control ob/ob mice and
modified by leptin administration. Leptin reduced the
mRNA levels of various isoforms of the family of heat shock
proteins (HSPs) (Dnajc16, Dnaja4, Dnajb4, Hspa2, Hspa4,
and Hspb7), metallothioneins (Mt2, Mt4), crystallins (Cryab,
Crybb1) and RNA binding proteins (RBMs) (Rbm9, Rbm22)
in ob/ob mice (Table 5). In addition, histocompatibility 2,
complement component factor B H2-Bf and several genes
of the acute-phase response or inflammatory processes, such
as kallikrein 5 (Klk5), and serine (or cysteine) proteinase
inhibitor clade C member 1 (Serpinc1) and clade B member
1a (Serpinb1a), displayed an increased expression in ob/ob
mice that was reduced by leptin administration. On the
contrary, gene expression of Cryl1, Hsp105, Rbm5, and
H2-Aa were enhanced in ob/ob mice after treated with
leptin. Pair-feeding, which accounts for the decrease in food
intake that is independent of the direct action of leptin,
altered the expression of 1,960 genes, upregulating 984 while
downregulating 976 genes. In the context of a food intake
reduction as compared to the simple eﬀect due to the caloric
restriction, leptin administration further significantly altered
the expression of genes involved in processes encompassing
“immune response” (P = 5.53e−8) “defense response” (P =
3.83e−6), “response to oxidative stress” (P = 2.99e−5),
“positive regulation of T cell activation” (P = .0003) and
“positive regulation of immune cell mediated cytotoxicity”
(P = .0004) (Table 4). In particular, the gene array analysis
provided evidence for elevated Hspa4, Mt4, Crybb1, and Ser-
pinb8 mRNA levels in the pair-fed group as compared to the
leptin-treated ob/ob mice (Table 6). On the contrary, leptin
increased the gene expression of H2-Ab1 and H2-Eb1 in ob/ob
mice. To confirm the microarray data, the mRNA expression
of several representative transcripts was analyzed by Real-
Time PCR (Figure 2). In this sense, leptin administration
reduced the mRNA levels of the muscle atrophy-related
transcription factor forkhead box O1 (Foxo1) and of the E3
ubiquitin-ligases muscle atrophy F-box (MAFbx) and muscle
RING finger 1 (MuRF1) in leptin-treated ob/ob mice, while
no eﬀect of leptin was evidenced on the mRNA levels of the
transcriptional coactivator peroxisome proliferator-activated
receptor-γ coactivator-1α (Pgc1 α). The expression of the
selected genes was concordant with that of the microarray.
4. Discussion
Obesity is accompanied by a chronic proinflammatory state
associated not only with insulin resistance, but also with
muscular atrophy [4, 5]. Our study provides evidence that
leptin constitutes a negative regulator of oxidative stress and
inflammation in the gastrocnemius, which is a representative
skeletal muscle of the whole skeletal musculature. This
statement is supported by findings reported herein: (a) leptin
deficiency is accompanied by systemic and skeletal muscle
oxidative stress, muscle inflammation, and reduced muscle
mass; (b) systemic and skeletal muscle oxidative stress,
muscle atrophy and inflammation of ob/ob mice are reversed
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Table 4: Biological processes according to Gene Ontology (GO) and number of genes altered by leptin deficiency, leptin administration, and
pair-feeding in the gastrocnemius muscle of wild type and ob/ob mice.
Category Genes in Category
wild type vs ob/ob ob/ob vs leptin leptin vs pair-fed
Altered genes P value Altered genes P value Altered genes P value
GO:6950: response to stress 1156 61 .00314 69 .0187 22 .0757
GO:6952: defense response 1010 43 .182 47 .510 33 3.83e−6
GO:6955: immune response 835 36 .186 45 .165 33 5.53e−8
GO:45321: immune cell
activation
230 9 .475 13 .270 6 .0974
GO:46649: lymphocyte
activation
208 9 .359 13 .170 6 .0673
GO:6954: inflammatory
response
199 4 .938 4 .984 2 .7590
GO:50776: regulation of
immune response
148 9 .097 12 .0426 8 .00102
GO:6959: humoral immune
response
123 7 .169 8 .211 4 .0891
GO:42110: T cell activation 112 5 .396 7 .263 5 .0191
GO:30098: lymphocyte
diﬀerentiation
107 8 .0441 8 .123 4 .0597
GO:42113: B cell activation 101 3 .724 7 .188 3 .1610
GO:6800: oxygen and reactive
oxygen species metabolism
92 11 .00056 7 .135 7 .00027
GO:50778: positive regulation
of immune response
91 7 .0508 11 .0032 8 3.6e−5
GO:51249: regulation of
lymphocyte activation
89 7 .046 10 .00808 5 .0076
GO:19882: antigen
presentation
81 9 .0029 9 .0125 8 1.53e−5
GO:31098: stress-activated
protein kinase signaling
pathway
80 8 .00921 5 .313 1 .6690
GO:30333: antigen processing 78 11 .00013 13 5.65e−5 8 1.16e−5
GO:7254: JNK cascade 75 8 .00629 4 .461 1 .6450
GO:46651: lymphocyte
proliferation
67 2 .712 5 .199 2 .2340
GO:6979: response to
oxidative stress
65 9 .0006 7 .0303 7 2.99e−5
GO:50863: regulation of T cell
activation
62 5 .0779 6 .0667 5 .0016
GO:7249: I-kappaB
kinase/NF-kappaB cascade
61 2 .663 3 .542 3 .0512
GO:51251: positive regulation
of lymphocyte activation
58 6 .0196 10 .0003 5 .00118
GO:30217: T cell
diﬀerentiation
54 5 .0481 6 .0380 4 .00638
GO:9266: response to
temperature stimulus
54 12 4.78e−7 13 7.96e−7 1 .5260
GO:30183: B cell
diﬀerentiation
50 2 .554 3 .410 2 .1500
GO:50670: regulation of
lymphocyte proliferation
46 2 .509 3 .360 1 .4700
GO:50864: regulation of B cell
activation
46 2 .509 5 .0606 2 .1310
GO:42087: cell-mediated
immune response
44 1 .809 1 .876 2 .1220
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Table 4: Continued.
Category Genes in Category
wild type vs ob/ob ob/ob vs leptin leptin vs pair-fed
Altered genes P value Altered genes P value Altered genes P value
GO:50777: negative regulation
of immune response
43 3 .210 2 .599 1 .4480
GO:50870: positive regulation
of T cell activation
43 5 .0203 6 .0137 5 .000294
GO:42088: T-helper 1 type
immune response
41 1 .786 1 .857 2 .1080
GO:9408: response to heat 40 9 1.17e−5 12 1.54e−7 1 .4240
GO:45619: regulation of
lymphocyte diﬀerentiation
36 6 .00186 5 .0242 4 .00144
GO:42100: B cell proliferation 32 1 .699 5 .0150 2 .0709
GO:19884: antigen
presentation, exogenous
antigen
31 9 1.17e−6 9 7.62e−6 8 6.81e−9
GO:50851: antigen
receptor-mediated signaling
pathway
30 1 .676 3 .160 1 .3390
GO:50871: positive regulation
of B cell activation
30 1 .676 5 .0115 2 .0633
GO:51250: negative regulation
of lymphocyte activation
30 2 .304 1 .759 1 .3390
GO:50671: positive regulation
of lymphocyte proliferation
29 2 .290 3 .149 1 .3300
GO:1909: immune cell
mediated cytotoxicity
27 2 .262 2 .358 3 .00584
GO:45580: regulation of T cell
diﬀerentiation
26 5 .00232 5 .00617 4 .00041
GO:30888: regulation of B cell
proliferation
24 1 .594 3 .0975 1 .2820
GO:45621: positive regulation
of lymphocyte diﬀerentiation
22 4 .00788 5 .00288 3 .00323
GO:19886: antigen processing,
exogenous antigen via MHC
class II
21 9 2.37e−8 8 2.45e−6 8 1.98e−10
GO:45058: T cell selection 20 2 .167 1 .613 3 .00244
GO:50868: negative regulation
of T cell activation
20 1 .528 1 .613 1 .2410
G O:42591: antigen
presentation, exogenous
antigen via MHC class II
19 6 4.42e−5 6 .000157 6 1.47e−7
GO:45582: positive regulation
of T cell diﬀerentiation
19 4 .00456 5 .00143 3 .0021
GO:1910: regulation of
immune cell mediated
cytotoxicity
18 2 .141 2 .202 3 .00178
GO:19724: B cell mediated
immunity
18 1 .491 1 .574 1 .2200
GO:45577: regulation of B cell
diﬀerentiation
16 1 .452 1 .532 2 .0198
GO:46328: regulation of JNK
cascade
16 1 .452 2 .168 1 .1980
GO:30890: positive regulation
of B cell proliferation
14 1 .409 3 .0246 1 .1760
GO:45060: negative thymic T
cell selection
14 1 .409 1 .485 1 .1760
GO:51085: chaperone cofactor
dependent protein folding
13 2 .0809 4 .00234 3 .00066
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Table 4: Continued.
Category Genes in Category
wild type vs ob/ob ob/ob vs leptin leptin vs pair-fed
Altered genes P value Altered genes P value Altered genes P value
GO:1912: positive regulation
of immune cell mediated
cytotoxicity
11 1 .338 1 .407 3 .00039
GO:48002: antigen
presentation, peptide antigen
10 5 1.45e−5 5 4.39e−5 4 6.8e−6
GO:48005: antigen
presentation, exogenous
peptide antigen
7 5 1.33e−6 5 4.11e−6 4 1.17e−6
GO:45620: negative regulation
of lymphocyte diﬀerentiation
6 2 .0184 1 .248 1 .0794
GO:46330: positive regulation
of JNK cascade
4 1 .139 1 .173 1 .0537
GO:45581: negative regulation
of T cell diﬀerentiation
2 1 .0723 1 .0905 1 .0272
P values reflect the significance of change in prevalence of genes in each category under the leptin deficiency (ob/ob), leptin administration (leptin) and pair-
feeding (pair-fed) conditions in ob/ob mice to the expected prevalence of genes in each category. Statistically significant P values are highlighted in bold.
by leptin administration independently of the eﬀects of food
intake inhibition. Therefore, leptin is able to prevent the
muscle atrophy associated with obese and inflammatory
states.
Skeletal muscle constitutes an important target for leptin
playing a key role on the regulation of lipid and glucose
metabolism [20]. Since obese ob/ob mice exhibit an increased
oxidative stress and impaired immune response [14, 15] and
a reduced skeletal muscle mass [21] compared with their
lean littermates, we aimed to identify the genes related to
inflammatory processes diﬀerentially altered by leptin in the
gastrocnemius muscle of obese ob/ob mice. In particular,
86 transcripts encoding inflammation-related proteins were
shown to be modified by exogenous leptin administration.
However, it has to be taken into account that many of
these genes are multifunctional and may have important
functions in other biological processes. Among them, leptin
repressed the high expression levels of acute-phase reactants
and several members of the HSP and RBM families. In
addition, confirming a previous study of our group [6],
leptin treatment increased the reduced muscle weight of
gastrocnemius muscle of ob/ob mice. Taken together, these
data suggest that leptin may prevent the obesity-associated
inflammatory state and the muscle mass loss related to
inflammatory states in leptin-deficient ob/ob mice.
Leptin-deficient ob/ob and leptin receptor-deficient
db/db mice display many abnormalities in the immune
response similar to those observed in starved animals
and malnourished humans [14, 15, 22]. In this respect,
exogenous leptin replacement to ob/ob mice modulates
T cell responses in mice and prevents starvation-induced
immunosuppression, suggesting that lack of leptin is directly
involved in these immune system abnormalities [23, 24].
In agreement with these studies, our findings show that
leptin deficiency and administration diﬀerentially regulate
biological processes related to the immune response as
well as the T and B cell diﬀerentiation and activation in
gastrocnemius muscle of ob/ob mice.
Oxidative stress is defined as the imbalanced redox state
in which prooxidants overwhelm the antioxidant capacity,
resulting in an increased production of reactive oxygen
species (ROS), ultimately leading to oxidative damage of
cellular macromolecules. The major ROS is the superoxide
anion (•O2−). Dismutation of •O2− by superoxide dismu-
tase (SOD) produces hydrogen peroxide (H2O2), a more
stable ROS, which, in turn, is converted to water by catalase
and glutathione peroxidase (GPx) [25]. Oxidative stress is
increased in diabetes [26, 27] with leptin administration
reportedly improving insulin sensitivity in normal and
diabetic rodents [28–30]. However, the relationship between
leptin and oxidative stress has not been clearly exhibited.
Leptin stimulates in vitro ROS production by inflammatory
cells [31] and endothelial cells [32] and the level of systemic
oxidative stress in nonobese animals [33, 34], suggesting
a “prooxidative” role of leptin. However, administration
of recombinant leptin reduces the oxidative stress induced
by a high-fat diet in mice [35]. In this sense, findings of
our study show a high oxidative stress in diabetic ob/ob
mice, as reflected by increased TBARS concentrations in
serum and the gastrocemius muscle. These observations are
in agreement with a large number of studies related to
increased plasma TBARS or MDA in diabetic rats [36] and
humans [37]. Lipid peroxidation is a common index of free
radical mediated injury and induction of antioxidant enzyme
is a common cellular response [38]. More importantly,
leptin administration decreased serum and gastrocnemius
TBARS concentrations as compared to control ob/ob mice,
with TBARS levels in gastrocnemius muscle from pair-fed
ob/ob animals remaining very similar to those of control
ob/ob mice. In this sense, from a molecular perspective, our
results further show that transcript levels of Sod1, Gpx3
and glutathione S-transferase π 1 Gstp1 are downregulated
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Table 5: Genes involved in oxidative stress and inflammatory responses altered by leptin in the gastrocnemius muscle of ob/ob mice.
GeneBank Number Gene Symbol Gene Name
Fold change
Ratio
ob/ob leptin
Genes downregulated by leptin
NM 009804 Cat Catalase 1.47 1.13 0.77
NM 007705 Cirbp Cold inducible RNA binding protein 1.68 1.14 0.68
NM 009964 Cryab Crystallin, α B 1.32 1.15 0.87
NM 023695 Crybb1 Crystallin, β B1 2.21 1.39 0.63
NM 023646 Dnaja3 DnaJ (Hsp40) homolog, subfamily A, member 3 0.95 0.64 0.67
NM 021422 Dnaja4 Heat shock protein, DNAJ-like 4 0.88 0.30 0.34
NM 018808 Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 0.44 0.33 0.74
NM 026400 Dnajb11 DnaJ (Hsp40) homolog, subfamily B, member 11 1.11 0.93 0.84
NM 027287 Dnajb4 DnaJ (Hsp40) homolog, subfamily B, member 4 1.09 0.60 0.55
NM 019874 Dnajb5 DnaJ (Hsp40) homolog, subfamily B, member 5 1.03 0.73 0.72
NM 011847 Dnajb6 DnaJ (Hsp40) homolog, subfamily B, member 6 isoform c 0.70 0.47 0.67
NM 013760 Dnajb9 DnaJ (Hsp40) homolog, subfamily B, member 9 0.62 0.39 0.63
NM 007869 Dnajc1 DnaJ (Hsp40) homolog, subfamily C, member 1 0.82 0.52 0.63
NM 028873 Dnajc14 DnaJ (Hsp40) homolog, subfamily C, member 14 1.12 0.87 0.77
NM 172338 Dnajc16 DnaJ (Hsp40) homolog, subfamily C, member 16 1.15 0.66 0.57
NM 009584 Dnajc2 DnaJ (Hsp40) homolog, subfamily C, member 2 1.01 0.82 0.81
NM 008929 Dnajc3 DnaJ (Hsp40) homolog, subfamily C, member 3B 1.02 0.83 0.82
NM 016775 Dnajc5 DnaJ (Hsp40) homolog, subfamily C, member 5 0.74 0.50 0.67
NM 010344 Gsr Glutathione reductase 1 1.17 0.71 0.61
NM 008180 Gss Glutathione synthetase 1.13 0.88 0.78
NM 010357 Gsta4 Glutathione S-transferase, α 4 1.50 1.46 0.97
NM 010362 Gsto1 Glutathione S-transferase o 1 1.42 1.15 0.81
NM 008198 H2-Bf Histocompatibility 2, complement component factor B 2.00 1.44 0.72
NM 013558 Hspa1l Heat shock 70kDa protein 1-like 1.60 1.04 0.65
NM 008301 Hspa2 Heat shock protein 2 1.49 0.98 0.65
NM 008300 Hspa4 Heat shock protein 4 0.92 0.30 0.32
NM 031165 Hspa8 Heat shock protein 8 0.91 0.57 0.62
NM 010481 Hspa9a Heat shock protein 9 1.03 0.88 0.86
NM 024441 Hspb2 Heat shock protein 2 1.45 1.21 0.83
NM 019960 Hspb3 Heat shock protein 3 1.66 1.27 0.77
NM 013868 Hspb7 Heat shock protein family, member 7 1.83 0.35 0.19
NM 008302 Hspcb Heat shock protein 1, β 0.86 0.69 0.80
NM 008416 Junb Jun-B oncogene 0.59 0.36 0.61
NM 010592 Jund1 Jun D proto-oncogene 1.49 0.94 0.63
NM 008456 Klk5 Kallikrein 5 2.23 1.43 0.64
NM 026346 MAFbx Muscle atrophy F box 0.65 0.43 0.67
NM 008209 Mr1 Histocompatibility-2 complex class 1-like 1.19 0.98 0.82
NM 008630 Mt2 Metallothionein 2 1.11 0.50 0.46
NM 008631 Mt4 Metallothionein 4 1.27 1.03 0.81
NM 008872 Plat Plasminogen activator, tissue 1.56 1.12 0.72
NM 029397 Rbm12 RNA binding motif protein 12 1.40 1.03 0.74
NM 026453 Rbm13 RNA binding motif protein 13 1.01 0.87 0.86
NM 026434 Rbm18 RNA binding motif protein 18 0.94 0.59 0.63
BC080205 Rbm22 RNA binding motif protein 22 1.14 0.75 0.66
BC040811 Rbm28 Rbm28 protein 0.69 0.49 0.71
NM 172762 Rbm34 RNA binding motif protein 34 1.01 0.67 0.66
NM 009032 Rbm4 RNA binding motif protein 4 1.04 0.81 0.78
NM 148930 Rbm5 RNA binding motif protein 5 0.69 0.63 0.91
NM 144948 Rbm7 RNA binding motif protein 7 0.81 0.74 0.91
NM 025875 Rbm8a RNA binding motif protein 8a 0.91 0.69 0.76
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Table 5: Continued.
GeneBank Number Gene Symbol Gene Name
Fold change
Ratio
ob/ob leptin
NM 175387 Rbm9 RNA binding motif protein 9 isoform 2 1.96 0.46 0.23
NM 025429 Serpinb1a Serine (or cysteine) proteinase inhibitor, clade B, member 1a 2.73 2.09 0.77
NM 080844 Serpinc1 Serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1 4.98 1.93 0.39
NM 008871 Serpine1 Serine (or cysteine) proteinase inhibitor, clade E, member 1 2.12 0.97 0.46
NM 011340 Serpinf1 Serine (or cysteine) proteinase inhibitor, clade F, member 1 2.43 1.50 0.62
NM 009776 Serping1 Serine (or cysteine) proteinase inhibitor, clade G, member 1 1.41 1.15 0.81
NM 009776 Serping1 Serine (or cysteine) proteinase inhibitor, clade G, member 1 1.41 1.15 0.81
NM 013749 Tnfrsf12a Tumor necrosis factor receptor superfamily, member 12a 0.78 0.29 0.37
Genes upregulated by leptin
NM 030004 Cryl1 Crystallin λ 1 1.25 1.72 1.38
NM 016669 Crym Crystallin μ 1.37 1.64 1.19
NM 133679 Cryzl1 Crystallin, ζ (quinone reductase)-like 1 1.10 1.28 1.16
NM 008161 Gpx3 Glutathione peroxidase 3 isoform 2 0.47 0.54 1.15
NM 024198 Gpx7 Glutathione peroxidase 7 1.00 1.34 1.33
NM 010359 Gstm3 Glutathione S-transferase, μ 3 1.06 1.23 1.17
NM 010360 Gstm5 Glutathione S-transferase, μ 5 1.09 1.39 1.27
NM 013541 Gstp1 Glutathione S-transferase, π 1 0.87 1.04 1.20
NM 010361 Gstt2 Glutathione S-transferase, θ 2 1.21 1.70 1.40
NM 133994 Gstt3 Glutathione S-transferase, θ 3 1.53 1.69 1.11
NM 010363 Gstz1 Glutathione transferase zeta 1 (maleylacetoacetate isomerase) 1.13 1.24 1.10
NM 010378 H2-Aa Histocompatibility 2, class II antigen A, α 0.46 1.26 2.76
NM 010379 H2-Ab1 Histocompatibility 2, class II antigen A, β1 0.37 1.04 2.84
NM 010382 H2-Eb1 Histocompatibility 2, class II antigen E β 0.43 1.03 2.40
NM 010395 H2-T10 Histocompatibility 2, T region locus 10 1.11 1.41 1.27
NM 013559 Hsp105 Heat shock protein 105 0.41 0.73 1.79
NM 008303 Hspe1 Heat shock protein 1 (chaperonin 10) 0.67 0.98 1.48
AK 052911 MuRF1 M muscle RING finger 1 0.20 0.28 1.43
XM 131139 Rbm15 RNA binding motif protein 15 0.81 1.34 1.66
NM 197993 Rbm21 RNA binding motif protein 21 0.67 0.73 1.08
BC029079 Rbm26 Rbm26 protein 0.75 1.19 1.59
AK087759 Rbm27 RNA binding motif protein 27 0.88 1.19 1.36
NM 148930 Rbm5 RNA binding motif protein 5 0.77 1.18 1.55
NM 011251 Rbm6 RNA binding motif protein 6 isoform a 0.80 0.97 1.21
NM 207105 Rmcs1 histocompatibility 2, class II antigen A, β1 0.38 0.89 2.37
NM 011454 Serpinb6b Serine (or cysteine) proteinase inhibitor, clade B, member 6b 1.06 1.23 1.16
NM 009825 Serpinh1 Serine (or cysteine) proteinase inhibitor, clade H, member 1 0.65 0.99 1.53
NM 145533 Smox Spermine oxidase 0.41 1.23 3.00
AK080908 Sod1 Superoxide dismutase 0.58 0.62 1.07
NM 011723 Xdh Xanthine dehydrogenase 0.68 1.01 1.47
Diﬀerential expression of genes is indicated as fold changes with respect to the wild type group presenting only the genes which were significantly diﬀerent
(P < .05) between the leptin-treated and the ob/ob groups. Ratio: fold change value for leptin-treated between the ob/ob groups.
in control ob/ob mice as compared to wild type controls
being upregulated after leptin treatment. Furthermore, lep-
tin administration also upregulated Gpx7, glutathione S-
transferase μ 5 (Gstm5) and glutathione S-transferase θ 2
(Gstt2). On the contrary, the high expression of catalase
(Cat) was repressed by the exogenous injection of leptin to
ob/ob mice. These findings are in line with previous obser-
vations showing the restoration of the defective antioxidant
enzyme activity in plasma of ob/ob mice [39] and humans
with a leptin gene mutation [40].
Acute-phase reactants have been suggested to contribute
to the maintenance of the chronic low-grade inflammation
state involved in the progression of obesity and related
diseases [41]. Interestingly, our study provides evidence that
genes of the acute-phase response were altered in gastroc-
nemius muscle of ob/ob mice, which were counteracted by
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Table 6: Genes involved in oxidative stress and inflammatory responses altered by leptin in gastrocnemius muscle of ob/ob mice
independently of food intake restriction.
GeneBank Number Gene symbol Gene name Fold change
Genes downregulated by leptin
NM 023695 Crybb1 Crystallin, β B1 0.51
NM 021422 Dnaja4 Heat shock protein, DNAJ-like 4 0.63
NM 019739 Foxo1 Forkhead box O1 0.34
NM 008300 Hspa4 Heat shock protein 4 0.64
NM 013868 Hspb7 Heat shock protein family, member 7 0.34
NM 010592 Jund1 Jun D proto-oncogene 0.50
NM 008456 Klk5 Kallikrein 5 0.46
NM 008491 Lcn2 Lipocalin 2 0.34
NM 008631 Mt4 Metallothionein 4 0.63
NM 026346 MAFbx Muscle atrophy F box 0.37
AK 052911 MuRF1 M muscle RING finger 1 0.29
NM 011459 Serpinb8 Serine (or cysteine) proteinase inhibitor, clade B, member 8 0.38
NM 011459 Serpinb8 Serine (or cysteine) proteinase inhibitor, clade B, member 8 0.59
NM 008871 Serpine1 Serine (or cysteine) proteinase inhibitor, clade E, member 1 0.42
Genes upregulated by leptin
NM 009735 B2m β-2-microglobulin 1.92
NM 010361 Gstt2 Glutathione S-transferase, θ 2 1.94
NM 010379 H2-Ab1 Histocompatibility 2, class II antigen A, β 1 4.72
NM 010379 H2-Ab1 Histocompatibility 2, class II antigen A, β 1 3.66
NM 010386 H2-DMa Histocompatibility 2, class II, locus Dma 2.35
NM 010387 H2-DMb1 Histocompatibility 2, class II, locus Mb1 3.31
NM 010382 H2-Eb1 Histocompatibility 2, class II antigen E β 4.65
NM 013559 Hsp105 Heat shock protein 105 1,79
AK220167 Hspa4 MKIAA4025 protein 1,59
NM 207105 Rmcs1 Histocompatibility 2, class II antigen A, β 1 4.24
NM 207105 Rmcs1 Histocompatibility 2, class II antigen A, β 1 4.17
NM 009255 Serpine2 Serine (or cysteine) proteinase inhibitor, clade E, member 2 1.53
NM 009825 Serpinh1 Serine (or cysteine) proteinase inhibitor, clade H, member 1 2.21
NM 145533 Smox Spermine oxidase 4.67
Diﬀerential expression of genes is indicated as fold changes presenting only the genes which were significantly diﬀerent (P < .05) between the leptin-treated
and the pair-fed ob/ob groups.
exogenous leptin administration. Leptin reduced the elevated
gene expression of tissue-type plasminogen activator (Plat)
and lipocalin-2 (Lcn2), which are upregulated in many
inflammatory conditions [42, 43], including human obesity
[44]. In addition, a pivotal role for oxidative stress in the
pathogenesis of muscle wasting in disuse and in a variety
of pathological conditions is now being widely recognized
[45]. A potential link between oxidative stress and muscle
atrophy involves the redox regulation of the proteolytic
system [46]. Moreover, various inflammatory cytokines
induce oxidative stress [47] and muscle atrophy through
the activation of the lysosomal [48, 49] and the ubiquitin-
proteolysis system [50]. In this context, biological processes
related to oxidative stress and inflammatory responses were
altered in the gastrocnemius muscle of ob/ob mice and
improved following leptin treatment. In spite of the usual
upregulation of the E3 ubiquitin-ligases MAFbx and MuRF1
in most conditions associated with atrophy, their gene
expression levels in ob/ob were lower as compared to wild
type animals, although no statistically significant diﬀerences
were observed. Contrarily to what would be expected, leptin
administration prevented the increase of both MAFbx and
MuRF1 mRNA expression levels induced by pair-feeding
in ob/ob mice. A plausible explanation for this surprising
finding may relate to the fact that in extreme conditions
the energy homeostasis system is overriden whereby leptin
is able to inhibit muscular protein degradation associated
to food intake reduction. These data are in accordance
with a previous study of our group evidencing that leptin
replacement inhibits the ubiquitin proteolysis system activity
in leptin-deficient mice [6]. Muscle atrophy is associated
with increased expression of genes coding for RBM proteins
which facilitate the translation, protection, and restoration
of native RNA conformations during oxidative stress. It has
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Figure 2: Real-Time PCR analysis of peroxisome proliferator-activated receptor coactivator 1α (Pgc1a), forkhead box class O1 (Foxo1),
muscle atrophy F box (MAFbx) and muscle RING finger 1 (MuRF1) in gastrocnemius muscle of wild type (open), control ob/ob (closed),
pair-fed ob/ob (gray) and leptin-treated ob/ob (striped) mice (n = 5 per group). Data are presented as mean±SEM of the ratio between gene
expression and 18S rRNA. ∗P < .05 and ∗∗P < .01 by Kruskal-Wallis followed by Mann Whitney’s U test.
been suggested that the gene expression of RBM proteins may
increase as a compensatory mechanism in response to loss of
muscle proteins [51, 52]. Other proteins involved in oxidative
stress are metallothioneins, endogenous antioxidants [53]
that have been shown to be overexpressed in muscle atrophy
in rodents [54–56]. In the present work, we have observed
that administration of leptin inhibits the gene expression of
several members of the RBM (Rbm9, Rbm22) and metalloth-
ioneins (Mt2, Mt4) families in the gastrocnemius of ob/ob
mice, suggesting that leptin may modulate the inflammatory
and oxidative stress responses and consequently, the muscle
loss related to inflammatory states.
Genes involved in the chaperone system were also diﬀer-
entially expressed in ob/ob mice as compared to wild types
and modified by leptin treatment. HSPs represent a family
of molecular chaperones induced in response to cellular
stress, responsible for maintaining the structure of proteins
and contributing to the repair of damaged or malformed
proteins in highly oxidative and lipotoxic conditions. As a
result, HSPs are considered antiproteolytic proteins [57].
Muscle atrophy is also associated with an increased gene
expression of HSPs [58]. In fact, HSPs are repressed in
many rat models of skeletal muscle atrophy [54, 59, 60].
HSP70 is constitutively expressed in skeletal muscle, but its
levels are increased in response to oxidative stress [61] with
the induction of HSP70 expression by hyperthermia and
during inactivity attenuating muscle atrophy [62, 63]. In this
regard, a recent study has shown that HSP70 prevents muscle
atrophy induced by physical inactivity through inhibition
of the muscle atrophy-related transcription factor FoxO3a
and the expression of MAFbx and MuRF1 [64]. Among the
HSPs, HSP70 and αB-crystallin in particular, are considered
negative regulators of muscle cell apoptosis [65, 66] and may
inhibit the loss of nuclei taking place during muscle atrophy.
In addition, ROS induce the activity of FoxO [67] and gene
expression of members of the ubiquitin-proteolysis system
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in myotubes [68]. In this sense, our results provide evidence
that leptin inhibits the increased gene expression of diﬀerent
members of the HSPs (Hspb7, Dnajc16, Hspa4, Cryab, and
Crybb1) in the gastrocnemius muscle of ob/ob mice. Taken
together, the elevated expression of HSPs in the control and
pair-fed ob/ob groups suggests a high defense and stress
response in these mice. Moreover, induction of HSPs may
confer broader health benefits to patients who are insulin
resistant or diabetic [69]. In mammals, caloric restriction
has been shown to upregulate HSP induction [70, 71], while
expression of HSP72 has been found to be low in skeletal
muscle of patients with insulin resistance or type 2 diabetes
[72, 73]. Figueiredo et al. [74] have recently shown that leptin
downregulates HSP70 gene expression in chicken liver and
hypothalamus but not in muscle, which was independent of
food intake restriction. On the contrary, Bonior et al. [75]
reported an increase in HSP60 gene expression in pancreatic
cells by leptin.
Obesity is accompanied by a chronic proinflammatory
state resulting in an increase in circulating cytokines and
inflammatory markers. In this regard, inflammation pro-
duces metabolic alterations in skeletal muscle with both
inflammatory response and insulin resistance being associ-
ated with muscle mass loss. Findings of our study provide
evidence that systemic and skeletal muscle oxidative stress,
muscle atrophy and the elevated expression of genes involved
in oxidative stress and inflammation of ob/ob mice are
reversed by leptin administration. Taken together, these data
thereby support that leptin is able to prevent the muscle
atrophy associated with obese and inflammatory states in
ob/ob mice. Most obese people develop muscle atrophy in
spite of exhibiting high leptin circulating concentrations,
which may be explained by the leptin resistance present
in these patients. Our paper sheds light on the relation
between obesity and the loss of muscle mass associated to
inflammatory states suggesting that leptin treatment may be
an attractive therapeutic approach to prevent muscle loss
associated with inflammatory diseases.
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